Novel Agent Reduces Seizures in Treatment-Resistant Epilepsy

(MedPage Today) -- Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the phase III X-TOLE2 trial showed. Over 12 weeks, adjunctive treatment with 25 mg azetukalner...
Source
MedPage Today
Opens original article in a new tab



